{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:06:04Z","timestamp":1794391564158,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["n\/a - investigator initiated research"],"award-info":[{"award-number":["n\/a - investigator initiated research"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research; philanthropic gift to Yale University."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids. An imprecise understanding of the immunologic changes underlying sarcoidosis has limited therapeutic progress. Here in this open-label trial (NCT03910543), 10 patients with cutaneous sarcoidosis are treated with tofacitinib, a Janus kinase inhibitor. The primary outcome is the change in the cutaneous sarcoidosis activity and morphology instrument (CSAMI) activity score after 6 months of treatment. Secondary outcomes included change in internal organ involvement, molecular parameters, and safety. All patients experience improvement in their skin with 6 patients showing a complete response. Improvement in internal organ involvement is also observed. CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell-derived IFN-\u03b3 is identified as a central cytokine mediator of macrophage activation in sarcoidosis. Additional type 1 cytokines produced by distinct cell types, including IL-6, IL-12, IL-15 and GM-CSF, also associate with pathogenesis. Suppression of the activity of these cytokines, especially IFN-\u03b3, correlates with clinical improvement. Our results thus show that tofacitinib treatment is associated with improved sarcoidosis symptoms, and predominantly acts by inhibiting type 1 immunity.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-30615-x","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T06:07:34Z","timestamp":1654495654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0975-4071","authenticated-orcid":false,"given":"William","family":"Damsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-4398","authenticated-orcid":false,"given":"Joseph","family":"Daccache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigale","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-084X","authenticated-orcid":false,"given":"Ruveyda","family":"Ayasun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwan","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7158","authenticated-orcid":false,"given":"Meaghan K.","family":"McGeary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Odell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Fazzone-Chettiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Pucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2055-5885","authenticated-orcid":false,"given":"Robert","family":"Homer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridu","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1612","authenticated-orcid":false,"given":"Marcus","family":"Bosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0778","authenticated-orcid":false,"given":"Richard A.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"30615_CR1","doi-asserted-by":"publisher","unstructured":"Rahaghi, F. F. et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev 29, https:\/\/doi.org\/10.1183\/16000617.0146-2019 (2020).","DOI":"10.1183\/16000617.0146-2019"},{"key":"30615_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chest.2020.03.001","volume":"158","author":"MA Judson","year":"2020","unstructured":"Judson, M. A. Causes of Poor Medication Adherence in Sarcoidosis: Poor Patient-Doctor Communication and Suboptimal Drug Regimens. Chest 158, 17\u201318 (2020).","journal-title":"Chest"},{"key":"30615_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1183\/09031936.00156314","volume":"44","author":"DR Moller","year":"2014","unstructured":"Moller, D. R. Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Eur. Respir. J. 44, 1123\u20131126 (2014).","journal-title":"Eur. Respir. J."},{"key":"30615_CR4","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1183\/09031936.00051907","volume":"31","author":"MA Judson","year":"2008","unstructured":"Judson, M. A. et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur. Respir. J. 31, 1189\u20131196 (2008).","journal-title":"Eur. Respir. J."},{"key":"30615_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman, R. P. et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med 174, 795\u2013802 (2006).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"30615_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1378\/chest.08-1347","volume":"135","author":"E Stagaki","year":"2009","unstructured":"Stagaki, E., Mountford, W. K., Lackland, D. T. & Judson, M. A. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 135, 468\u2013476 (2009).","journal-title":"Chest"},{"key":"30615_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","volume":"68","author":"RJ Pariser","year":"2013","unstructured":"Pariser, R. J., Paul, J., Hirano, S., Torosky, C. & Smith, M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J. Am. Acad. Dermatol 68, 765\u2013773 (2013).","journal-title":"J. Am. Acad. Dermatol"},{"key":"30615_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1183\/09031936.00000914","volume":"44","author":"MA Judson","year":"2014","unstructured":"Judson, M. A. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur. Respir. J. 44, 1296\u20131307 (2014).","journal-title":"Eur. Respir. J."},{"key":"30615_CR9","doi-asserted-by":"publisher","unstructured":"Murphy, M. J., Cohen, J. M., Vesely, M. D. & Damsky, W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol, https:\/\/doi.org\/10.1016\/j.jaad.2020.12.010 (2020).","DOI":"10.1016\/j.jaad.2020.12.010"},{"key":"30615_CR10","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi, M. C., Rybicki, B. A. & Teirstein, A. S. Sarcoidosis. N. Engl. J. Med. 357, 2153\u20132165 (2007).","journal-title":"N. Engl. J. Med."},{"key":"30615_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/thx.2010.140319","volume":"66","author":"M Facco","year":"2011","unstructured":"Facco, M. et al. Sarcoidosis is a Th1\/Th17 multisystem disorder. Thorax 66, 144\u2013150 (2011).","journal-title":"Thorax"},{"key":"30615_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/cei.12403","volume":"178","author":"M Ostadkarampour","year":"2014","unstructured":"Ostadkarampour, M. et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren\u2019s syndrome. Clin. Exp. Immunol. 178, 342\u2013352 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"30615_CR13","doi-asserted-by":"publisher","unstructured":"Broos, C. E. et al. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J 51, https:\/\/doi.org\/10.1183\/13993003.01124-2017 (2018).","DOI":"10.1183\/13993003.01124-2017"},{"key":"30615_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1165\/rcmb.2018-0053OC","volume":"60","author":"LW Locke","year":"2019","unstructured":"Locke, L. W. et al. IL-13-regulated Macrophage Polarization during Granuloma Formation in an In Vitro Human Sarcoidosis Model. Am. J. Respir. Cell Mol. Biol. 60, 84\u201395 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"30615_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/thorax.58.6.519","volume":"58","author":"HP Hauber","year":"2003","unstructured":"Hauber, H. P., Gholami, D., Meyer, A. & Pforte, A. Increased interleukin-13 expression in patients with sarcoidosis. Thorax 58, 519\u2013524 (2003).","journal-title":"Thorax"},{"key":"30615_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.clim.2009.04.010","volume":"132","author":"JT Rosenbaum","year":"2009","unstructured":"Rosenbaum, J. T. et al. Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin. Immunol. 132, 174\u2013183 (2009).","journal-title":"Clin. Immunol."},{"key":"30615_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.gene.2016.09.037","volume":"596","author":"H Li","year":"2017","unstructured":"Li, H., Zhao, X., Wang, J., Zong, M. & Yang, H. Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. Gene 596, 98\u2013104 (2017).","journal-title":"Gene"},{"key":"30615_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04109-6","volume":"7","author":"T Zhou","year":"2017","unstructured":"Zhou, T. et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci. Rep. 7, 4237 (2017).","journal-title":"Sci. Rep."},{"key":"30615_CR19","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","volume":"379","author":"W Damsky","year":"2018","unstructured":"Damsky, W., Thakral, D., Emeagwali, N., Galan, A. & King, B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N. Engl. J. Med. 379, 2540\u20132546 (2018).","journal-title":"N. Engl. J. Med."},{"key":"30615_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","volume":"82","author":"W Damsky","year":"2020","unstructured":"Damsky, W. et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J. Am. Acad. Dermatol. 82, 612\u2013621 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"30615_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/acr2.11112","volume":"2","author":"W Damsky","year":"2020","unstructured":"Damsky, W. et al. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatol. 2, 106\u2013109 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"30615_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","volume":"84","author":"KL Kerkemeyer","year":"2021","unstructured":"Kerkemeyer, K. L., Meah, N. & Sinclair, R. D. Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series. J. Am. Acad. Dermatol. 84, 581\u2013583 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"30615_CR23","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","volume":"78","author":"M Levraut","year":"2019","unstructured":"Levraut, M., Martis, N., Viau, P., Suarez, F. & Queyrel, V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann. Rheum. Dis. 78, 1606\u20131607 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"30615_CR24","doi-asserted-by":"publisher","unstructured":"Rotenberg, C. et al. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir. J. 52, https:\/\/doi.org\/10.1183\/13993003.01482-2018 (2018).","DOI":"10.1183\/13993003.01482-2018"},{"key":"30615_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","volume":"5","author":"JJ Wei","year":"2019","unstructured":"Wei, J. J., Kallenbach, L. R., Kreider, M., Leung, T. H. & Rosenbach, M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 5, 360\u2013361 (2019).","journal-title":"JAAD Case Rep."},{"key":"30615_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMra2101555","volume":"385","author":"M Drent","year":"2021","unstructured":"Drent, M., Crouser, E. D. & Grunewald, J. Challenges of Sarcoidosis and Its Management. N. Engl. J. Med 385, 1018\u20131032 (2021).","journal-title":"N. Engl. J. Med"},{"key":"30615_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","volume":"5","author":"J Grunewald","year":"2019","unstructured":"Grunewald, J. et al. Sarcoidosis. Nat. Rev. Dis. Prim. 5, 45 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"30615_CR28","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.jaci.2020.11.028","volume":"147","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer. J. Allergy Clin. Immunol. 147, 2370\u20132380 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"30615_CR29","doi-asserted-by":"publisher","unstructured":"Liao, S. Y. et al. Single-cell RNA sequencing identifies macrophage transcriptional heterogeneities in granulomatous diseases. Eur. Respir. J 57, https:\/\/doi.org\/10.1183\/13993003.03794-2020 (2021).","DOI":"10.1183\/13993003.03794-2020"},{"key":"30615_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1164\/rccm.202005-1989OC","volume":"203","author":"KJ Mould","year":"2021","unstructured":"Mould, K. J. et al. Airspace macrophages and monocytes exist in transcriptionally distinct subsets in healthy adults. Am. J. Respir. Crit. Care Med. 203, 946\u2013956 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"30615_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jaad.2011.06.017","volume":"66","author":"MA Judson","year":"2012","unstructured":"Judson, M. A. et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J. Am. Acad. Dermatol. 66, 901\u2013910 (2012). 910 e901-902.","journal-title":"J. Am. Acad. Dermatol."},{"key":"30615_CR32","doi-asserted-by":"publisher","unstructured":"Vukmirovic, M. et al. Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. Eur. Respir. J. 58, https:\/\/doi.org\/10.1183\/13993003.02950-2020 (2021).","DOI":"10.1183\/13993003.02950-2020"},{"key":"30615_CR33","doi-asserted-by":"publisher","first-page":"108974","DOI":"10.1016\/j.celrep.2021.108974","volume":"35","author":"MJ Camiolo","year":"2021","unstructured":"Camiolo, M. J. et al. High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status. Cell Rep. 35, 108974 (2021).","journal-title":"Cell Rep."},{"key":"30615_CR34","doi-asserted-by":"publisher","unstructured":"Lepzien, R. et al. Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome. Eur. Respir. J. 58, https:\/\/doi.org\/10.1183\/13993003.03468-2020 (2021).","DOI":"10.1183\/13993003.03468-2020"},{"key":"30615_CR35","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.xjidi.2021.100021","volume":"1","author":"A Wang","year":"2021","unstructured":"Wang, A. et al. Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. JID Innov. 1, 100021 (2021).","journal-title":"JID Innov."},{"key":"30615_CR36","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"30615_CR37","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1172\/JCI111852","volume":"75","author":"BW Robinson","year":"1985","unstructured":"Robinson, B. W., McLemore, T. L. & Crystal, R. G. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J. Clin. Invest 75, 1488\u20131495 (1985).","journal-title":"J. Clin. Invest"},{"key":"30615_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1164\/ajrccm\/143.1.53","volume":"143","author":"C Prior","year":"1991","unstructured":"Prior, C. & Haslam, P. L. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am. Rev. Respir. Dis. 143, 53\u201360 (1991).","journal-title":"Am. Rev. Respir. Dis."},{"key":"30615_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1465-9921-14-121","volume":"14","author":"R Su","year":"2013","unstructured":"Su, R. et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir. Res 14, 121 (2013).","journal-title":"Respir. Res"},{"key":"30615_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.rmed.2019.04.005","volume":"152","author":"NK Arger","year":"2019","unstructured":"Arger, N. K., Ho, M., Woodruff, P. G. & Koth, L. L. Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis. Respir. Med 152, 89\u201396 (2019).","journal-title":"Respir. Med"},{"key":"30615_CR41","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","volume":"178","author":"JL Flynn","year":"1993","unstructured":"Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med 178, 2249\u20132254 (1993).","journal-title":"J. Exp. Med"},{"key":"30615_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1084\/jem.158.3.670","volume":"158","author":"CF Nathan","year":"1983","unstructured":"Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med 158, 670\u2013689 (1983).","journal-title":"J. Exp. Med"},{"key":"30615_CR43","first-page":"502","volume":"43","author":"AL Croxford","year":"2015","unstructured":"Croxford, A. L. et al. The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Auto. Immun. Immun. 43, 502\u2013514 (2015).","journal-title":"Immun. Immun."},{"key":"30615_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cyto.2017.08.004","volume":"99","author":"AT Waickman","year":"2017","unstructured":"Waickman, A. T. et al. CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans. Cytokine 99, 266\u2013274 (2017).","journal-title":"Cytokine"},{"key":"30615_CR45","doi-asserted-by":"publisher","unstructured":"Sharp, M., Donnelly, S. C. & Moller, D. R. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X 1, https:\/\/doi.org\/10.1016\/j.yrmex.2019.100004 (2019).","DOI":"10.1016\/j.yrmex.2019.100004"},{"key":"30615_CR46","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0954-6111(03)00127-6","volume":"97","author":"H Yanardag","year":"2003","unstructured":"Yanardag, H., Pamuk, O. N. & Karayel, T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir. Med. 97, 978\u2013982 (2003).","journal-title":"Respir. Med."},{"key":"30615_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamadermatol.2013.60","volume":"149","author":"M Rosenbach","year":"2013","unstructured":"Rosenbach, M. et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol 149, 550\u2013556 (2013).","journal-title":"JAMA Dermatol"},{"key":"30615_CR48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","volume":"5","author":"MM Chren","year":"2001","unstructured":"Chren, M. M., Lasek, R. J., Sahay, A. P. & Sands, L. P. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J. Cutan. Med Surg. 5, 105\u2013110 (2001).","journal-title":"J. Cutan. Med Surg."},{"key":"30615_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","volume":"21","author":"A Ahmadian","year":"2014","unstructured":"Ahmadian, A. et al. Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J. Nucl. Cardiol. 21, 925\u2013939 (2014).","journal-title":"J. Nucl. Cardiol."},{"key":"30615_CR50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1007\/s12350-017-1057-y","volume":"24","author":"PL Tilkemeier","year":"2017","unstructured":"Tilkemeier, P. L., Bourque, J., Doukky, R., Sanghani, R. & Weinberg, R. L. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. J. Nucl. Cardiol. 24, 2064\u20132128 (2017).","journal-title":"J. Nucl. Cardiol."},{"key":"30615_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11886-013-0370-6","volume":"15","author":"H Skali","year":"2013","unstructured":"Skali, H., Schulman, A. R. & Dorbala, S. (18)F-FDG PET\/CT for the assessment of myocardial sarcoidosis. Curr. Cardiol. Rep. 15, 352 (2013).","journal-title":"Curr. Cardiol. Rep."},{"key":"30615_CR52","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12350-017-0978-9","volume":"24","author":"P Chareonthaitawee","year":"2017","unstructured":"Chareonthaitawee, P. et al. Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring. J. Nucl. Cardiol. 24, 1741\u20131758 (2017).","journal-title":"J. Nucl. Cardiol."},{"key":"30615_CR53","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med 50, 122S\u2013150S (2009).","journal-title":"J. Nucl. Med"},{"key":"30615_CR54","unstructured":"H. Wan, R. N., A. S. Nelson. in Annual Congress of the European Association of Nuclear Medicine S253 (D\u00fcsseldorf, Germany)."},{"key":"30615_CR55","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-Handel","year":"2019","unstructured":"Witte-Handel, E. et al. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. J. Invest Dermatol 139, 1294\u20131305 (2019).","journal-title":"J. Invest Dermatol"},{"key":"30615_CR56","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30615_CR57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","volume":"9","author":"TS Heng","year":"2008","unstructured":"Heng, T. S., Painter, M. W. & Immunological Genome Project, C. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091\u20131094 (2008).","journal-title":"Nat. Immunol."},{"key":"30615_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin, A., Frey, T., Christiansen, S. L. & Committee, A. M. A. M. O. S. Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. JAMA 326, 621\u2013627 (2021).","journal-title":"JAMA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30615-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:49:51Z","timestamp":1669294191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30615-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30615"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30615-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.D. has research funding from Pfizer and Advanced Cell Diagnostics\/Bio-techne, serves as a consultant for Eli Lilly, Pfizer, Incyte, and Twi Biotechnology, and receives licensing fees from EMD\/Millipore\/Sigma. B.D.Y receives research funding from Pfizer. E.J.M. receives research funding from Alnylam, Pfizer, and Eidos and serves as a consultant for Alnylam, Pfizer, and Eidos. D.P. receives consulting fees from Telix Pharmaceuticals and Cohere Health. M.B. is a consultant for Eli Lilly and receives licensing fees from EMD\/Millipore\/\/Sigma. R.A.F. is a consultant for Glaxo Smith Kline and Zai labs. B.K. is a consultant to and\/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer, and VielaBio; he is on speaker\u2019s bureau for Pfizer, Regeneron and Sanofi Genzyme. A.W., D.J.K., K.S., M.J.M., J.D., A.C., R.A., C.R., M.K.M., I.D.O., R.F.C., R.H. and M.G. have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3140"}}